RVNC’s share price dropped when ABBV said during its 2Q23 CC that Daxxify was garnering a low-single-digit share of the US aesthetics market.
I can't be upset with ABBV's comments about Daxxify as ABBV is up $7/share or 5% so far today on strong drug sales. ABBV's fate doesn't rely on Botox so both RVNC & ABBV can do well.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.